Cocrystal Pharma
COCP
24 hedge funds and large institutions have $3.2M invested in Cocrystal Pharma in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 4 closing their positions.
350% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 2
85% more capital invested
Capital invested by funds: $1.73M → $3.2M (+$1.47M)
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
9% more funds holding
Funds holding: 22 → 24 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.11% less ownership
Funds ownership: 0.83% → 0.72% (-0.11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.09M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$393K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$308K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$140K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$137K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$892K |
| 2 |
SS
Sunbelt Securities
Houston,
Texas
|
-$6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$5.12K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2K |
| 5 |
SBH
Segall Bryant & Hamill
Chicago,
Illinois
|
-$1.18K |
COCP Hedge Fund Activity: Q1 2020 in Review
24 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q1 2020, worth a combined $3.2M — up 85% from $1.73M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new COCP positions and 4 closed out — a net gain of 3 holders — while 9 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $1.09M. The largest seller was Wasatch Advisors, exiting entirely with an estimated $892K sold.
- 24 institutional investors held Cocrystal Pharma (COCP) as of Q1 2020, up from 22 in Q4 2019.
- Funds reported $3.2M of Cocrystal Pharma stock for Q1 2020, up 85% quarter-over-quarter.
- 7 funds opened new Cocrystal Pharma positions in Q1 2020 and 4 closed out, a net change of +3 holders.
- The largest Cocrystal Pharma buyer in Q1 2020 was Renaissance Technologies, an estimated $1.09M added.
- The largest Cocrystal Pharma seller in Q1 2020 was Wasatch Advisors, an estimated $892K sold.
Based on aggregated 13F filings for Q1 2020.